HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...

Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

Medical announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using ...

Individuals with chronic, untreated hepatitis C virus infection may be at greater risk for pancreatic ductal adenocarcinoma, ...

Pancreatic ductal adenocarcinoma (PDAC), is highly aggressive and lethal. It is the most prevalent type of pancreatic cancer, making up 90% of cases; it also has a high rate of metastasis, with an ...

Now, researchers are turning to an unexpected source for early PDAC detection: faecal samples. While analysing poo might seem ...

Researchers from the School of Pharmacy and Pharmaceutical Sciences recently published a paper in Molecular & Cellular Proteomics, a top international proteomics journal, describing their work in ...